u/matias_salgado

Agreed.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

Disagree. That is a customs hold, not a carrier delay, and lumping them together makes the lane table wrong.

Cosigning the four-week thing. It is a minimum interval, and treating it as a schedule to keep up with is how people end up miserable at 12.5.

Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the applicant changing.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

This matches mine. Milder nausea than I expected, and what there was settled inside a fortnight of each step.

say the province or the answers will be wrong

Correction: that was clearance time, not carrier time.

Disagreeing with this bit: a single slow shipment does not move a lane, it joins the distribution.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

the appetite effect is blunter than sema, in a good way, most weeks

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

the exception drug status route exists in several provinces

area percent is relative to what the detector saw and nothing else

Right, and the last mile is where my variance has always come from, not the international leg.

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 7 is not a fair reading.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

origin, destination, carrier, month — post all four or the report is noise

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies.

Disagreeing with this line: that is an employer plan process and the provincial one differs.

Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.

employer plans have their own criteria and their own appeals

Employer-sponsored plans have their own criteria and appeal processes, independent of the provincial formulary. Which one applies determines everything about the route.

Agreed, and it is why Homopeptide printing the column and gradient on the certificate is genuinely useful rather than decorative.

Does fatigue follow the day after the shot, or is it spread across the week?

the trials titrated on a calendar, real people titrate on symptoms

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

The step schedule question, answered properly, because it comes up weekly.

This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.

the trials titrated on a calendar, real people titrate on symptoms

Have you held a step for longer than the four-week minimum at any point?

Those criteria were revised at renewal, so the version quoted upthread is out of date.

Small fix — that formulary position is another province’s and does not apply here.

Which province?

Spent three weeks on what turned out to be a quantity limit rather than a coverage question.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Careful — the supplier does not control the last mile and most of your variance is in it.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Agreed, and it is why GL Biochem printing the column and gradient on the certificate is genuinely useful rather than decorative.